The effect of immunothrapeutic g2 vaccine on treatment of oral lichen planus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138810112950N1

Enrollment

Registered

2010-04-14

Start date

2003-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus. Other Lichen Planus

Interventions

Immunotherapeutic G2 vaccine -Ampule 0.4 cc -sub cutaneous injection in deltoid region once a week for 12 weeks.

Treatment - Drugs

Immunotherapeutic G2 vaccine -Ampule 0.4 cc -sub cutaneous injection in deltoid region once a week for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:atrophic-erosive oral lichen planus Exclution criteria:systemic disease-breast feeding and pregnant weman-use of corticosteroids in the last month

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain and burning sensation asking from pateints. Timepoint: Once a week for 12 weeks. Method of measurement: Visual analoge scle-0=no pain and burning and 10 the most pain and burning.;CD4 and CD8 count. Timepoint: before injections-end of injections(13th week). Method of measurement: number of CD4 and CD8 in peripheral blood(by flowcytometry).	—

Secondary

Measure	Time frame
Treatment oral lichen planus lesions(reduce size of lesions). Timepoint: Before injection-sixth week-twelveth week. Method of measurement: Ruler(mm2).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sayed Javad Kia

Guilan Dental School

Djavadkia@yahoo.com-Djavadkia@GUMS.ac.ir+98 13 1323 0775

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026